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Does psychological stress in patients with
clinically suspect arthralgia associate with
subclinical inflammation and progression
to inflammatory arthritis?
Aleid C. Boer1*, Robin M. ten Brinck1, Andrea W. M. Evers2 and Annette H. M. van der Helm-van Mil1,3
Abstract
Background: Within established rheumatoid arthritis (RA), stress can have pro-inflammatory effects by activating
the immune system via the hypothalamic-pituitary-adrenal axis and the autonomic nervous system. It is unknown
if stress levels also promote inflammation during RA development. We studied whether the psychological stress
response was increased in clinically suspect arthralgia (CSA) and if this associated with inflammation at presentation
with arthralgia and with progression to clinical arthritis.
Methods: In 241 CSA patients, psychological stress was measured by the Mental Health Inventory (MHI-5) and the
Perceived Stress Scale (PSS-10) at first presentation and during follow-up. Systemic inflammation was measured by
C-reactive protein (CRP) and joint inflammation by 1.5 T-MRI of wrist, MCP, and MTP joints.
Results: At baseline, 12% (24/197) of CSA patients had a high psychological stress response according to the MHI-5.
This was not different for patients presenting with or without an elevated CRP, with or without subclinical MRI-
detected inflammation and for patients who did or did not develop arthritis. Similar findings were obtained with
the PSS-10. When developing clinical arthritis, the percentage of patients with ‘high psychological stress’ increased to
31% (p = 0.025); during the first year of treatment this decreased to 8% (p = 0.020). ‘High psychological stress’ in non-
progressors remained infrequent over time (range 7–13%). Stress was associated with fatigue (p = 0.003) and wellbeing
(p < 0.001).
Conclusions: Psychological stress was not increased in the phase of arthralgia, raised at the time of diagnoses and
decreased thereafter. The lack of an association with inflammation in arthralgia and this temporal relationship, argue
against psychological stress having a significant contribution to progression from CSA to inflammatory arthritis.
Keywords: Inflammation, Rheumatoid arthritis, C-reactive protein (CRP), Magnetic resonance imaging (MRI), Psychological
status
Background
In chronic inflammatory diseases like rheumatoid arthritis
(RA), psychological stress is considered to negatively affect
the disease course. It activates the hypothalamic-pituitary-
adrenal axis and the autonomic nervous system, which
associate with the release of neurotransmitters (i.e. norepin-
ephrine), hormones (i.e. cortisol) and activation of immune
cells [1–3]. During stress, the normal downregulation of
the inflammatory response is hindered, possibly causing
pro-inflammatory effects. Despite these effects, it is pres-
ently unknown if stress mediates the development of early
inflammatory arthritis or RA.
The prevalence and the effects of psychological stress
have been thoroughly investigated within patients with
established RA. Compared to the general population, RA
patients experience more stress [4]. Moreover the stress
response is deranged, especially in patients with in-
creased disease activity scores and disease exacerbations
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[5–8]. Patients have increased stress-induced inflamma-
tory cytokine levels (i.e., interleukin (IL)-6, IL-1b, IL-2)
and impairments in the capacity of glucocorticoids to
inhibit this inflammatory response [9–11]. Likewise, psy-
chological stress has been associated with increased C-
reactive protein (CRP) levels [1, 12]. Furthermore, re-
search in patients with established RA has indicated that
pre-existing inflammation can facilitate stress-induced
inflammation [2, 12], potentially inducing a vicious circle
between psychological stress and inflammation. Notably,
the pro-inflammatory effects observed in these studies
were independent of the disease duration [6, 13, 14].
The developmental course of RA is incompletely
understood, though it is recognized that it consists of
several phases [15]. The phase preceding that of clinic-
ally apparent (chronic) arthritis is a symptomatic one,
called clinically suspect arthralgia (CSA). CSA patients
have a combination of clinical characteristics that are
recognizable by rheumatologists, and are at risk to de-
velop RA [16]. These characteristics were also recently
described by a EULAR taskforce [17]. Part of the CSA
patients have subclinical joint inflammation that is de-
tectable by MRI at first presentation to a rheumatologist
[18], and subclinical inflammation is present in the vast
majority of those CSA patients that progress to RA [16].
It is presumed that biologic mechanisms evolving in
this symptomatic pre-arthritis phase of RA are import-
ant for the future course of the disease. Whether psy-
chological stress is associated with inflammation in the
phase of CSA or with progression to clinically apparent
arthritis or RA is presently unknown and subject of this
study. Based on the abovementioned observations in
patients with established RA, stress might contribute to
the development of subclinical inflammation and sub-
sequently mediate progression to RA. The recent obser-
vation that life events pose a (small) risk at
development of RA fits into this hypothesis [5]. How-
ever alternatively, stress can also be a consequence of
symptoms and physical limitations without having ex-
acerbating effects on inflammation in the phase of
CSA. To increase the comprehension of the effects of
the perceived psychological stress response in a symp-
tomatic pre-arthritis phase, this study aimed to deter-
mine associations and time-relationships between stress
and inflammation in patients presenting with CSA and
during progression to early clinical arthritis. The psy-
chological stress response was measured by two vali-
dated questionnaires, the five-item Mental Health
Inventory (MHI-5) and Cohen’s perceived stress scale
(PSS-10) [19–21]. Inflammation was measured by sys-
temic inflammation assessed using C-reactive protein
(CRP) levels and subclinical joint inflammation deter-
mined using magnetic resonance imaging (MRI) of
hand and foot joints.
Methods
Patient population
Patients included in the Leiden Clinically Suspect Arthralgia
(CSA) cohort between April 2012 and March 2015 were
studied. The CSA cohort is a population-based inception
cohort that started at the rheumatology outpatient clinic in
Leiden, The Netherlands, with the aim of studying the
symptomatic phase of RA that precedes clinical arthritis. In-
clusion required the presence of arthralgia of small joints
for < 1 year which was because of the character of the
symptoms, considered as being suspect to progress to RA
by a rheumatologist. A detailed description is provided else-
where [16], but identification of CSA occurred mainly by
the clinical expertise of the rheumatologist. Furthermore,
CSA was identified at the first visit, before the results of
routine laboratory investigations were known. Notably, gen-
eral practitioners in our region are discouraged to perform
anti-citrullinated protein antibodies (ACPA) testing them-
selves but are encouraged to refer in a case of any suspicion
on imminent RA. After inclusion in the CSA cohort, rou-
tine visits were performed after 4 months, 1 year and 2 years.
At the request of patients (e.g. in case they experienced
more symptoms) patients were also seen in between the
scheduled visits. All patients were followed for development
of clinically apparent arthritis for 2 years. Follow-up in the
CSA cohort ended earlier when clinical synovitis had devel-
oped, confirmed with joint swelling at physical examination
by the treating rheumatologist. CSA patients were not
treated with disease-modifying anti-rheumatic drugs
(DMARDs) or corticosteroids in the phase of CSA. For the
patients that developed clinical synovitis, further data was
obtained as they were subsequently included in the Leiden
Early Arthritis Clinic (EAC) cohort [22]. Data collected at
clinical arthritis onset and 1 year thereafter were used. Pa-
tients who were diagnosed with RA were treated in con-
formance with national guidelines, which consists of early
initiation with a DMARD (preferably methotrexate), in case
of failure a second conventional DMARD (either switching
or adding) and disease activity score (DAS)-steered treat-
ment adjustments. Biologics were allowed if ≥2 conven-
tional DMARDs failed but that this did not occur in the
studied period of 1 year after clinical arthritis onset. A flow-
chart of the study protocol is available in Additional file 1:
Figure S1. Written informed consent was obtained from all
patients. The study was approved by the local medical ethics
committee.
Study protocol
At each visit physical examinations, including 66-
swollen and 68-tender joint counts (66-SJC and 68-TJC)
were performed and blood samples were taken to meas-
ure CRP (positive if ≥5 mg/L); immunoglobulin M-
rheumatoid factor (RF) (positive if ≥3.5 IU/mL); and
ACPA (anti-CCP2, EliA CCP, Phadia, The Netherlands,
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positive if ≥7 U/mL). Questionnaires were completed,
including the health assessment questionnaire (HAQ)-
disability index (DI), 36-item Short Form Health Survey
(SF-36) and self-reported wellbeing, pain and fatigue on
numerical rating scales ranging from 0 (no complaints)
to 10 (extreme complaints). The PSS-10 was added later
to the protocol in 2013 and was gathered only at base-
line. Further, to measure subclinical joint inflammation,
MRI scans of metacarpophalangeal (MCP), wrist and
metatarsophalangeal (MTP joints were made of the most
affected side (or the dominant side in case of equally se-
vere symptoms) on an MSK Extreme 1.5 T extremity
MR-system (GE, \Milwaukee, WI, USA). MRI scans were
made of the same side at baseline and at arthritis onset
(before the start of disease-modifying drugs including
corticosteroids) and 1 year thereafter. Non-steroidal
anti-inflammatory drugs (NSAIDs) were stopped 24 h
before the MRI scan. The scans were scored for MRI-
detected inflammation according to the Outcome Mea-
sures in Rheumatology Clinical Trials (OMERACT) RA
MRI scoring (RAMRIS) method as described supple-
mentary and previously published [16]. Total inflamma-
tion scores consisted of the sum of synovitis, bone
marrow edema (BMO) and tenosynovitis scores. All
scans were scored by two independent readers and mean
scores of both readers were calculated to obtain the total
inflammation score (see Additional file 1: Supplementary
Methods). The cut-off of MRI positivity was based on
healthy controls as described previously [23]. An MRI
was considered positive for subclinical inflammation
(tenosynovitis, synovitis or BMO) if this was present in
< 5% of healthy volunteers (an example is provided in
the Additional file 1: Supplementary Methods).
Psychological stress questionnaires
The psychological stress response was measured by two
questionnaires. First, for the main analyses we used the
MHI-5 which is a component of the SF-36 questionnaire
[19, 24]. Baseline MHI-5 was missing in 18% of the CSA
patient and no differences were found in baseline char-
acteristics between patients with an available and miss-
ing MHI-5 (Additional file 1: Table S1). The MHI-5 is a
brief self-administered questionnaire which includes
scales to screen for anxiety and depression [20, 25]. It is
well-validated with good psychometric properties for
detecting Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) type I axis diagnoses [26], these dis-
orders include clinical mental disorders like anxiety and
depression [27]. The MHI-5 has a Cronbach’s α between
0.74 and 0.90 [19, 26]. The items were scored on a six-
point frequency rating scale and questions are provided
in the Additional file 1: Supplementary Methods. After
linear conversion, possible scores on the MHI-5 range
from 0 to 100, with lower scores reflecting a higher
stress response. As the score has been considered as a
dichotomous variable (absence or presence of a psycho-
logical stress response), a score ≥ 52 indicated minimal
psychological stress (anxiety or depression) and < 52
high psychological stress; here simply called ‘high stress’.
The application of this questionnaire to screen for stress
by means of depression and anxiety has been examined
thoroughly, as illustrated by several studies [25, 26, 28].
Second, to investigate the main results on stress
further we analysed the PSS-10. As this questionnaire
was added to the protocol at a later time point, PSS-
10 data was missing in 44% of CSA patients. No dif-
ferences were found in baseline characteristics
between patients with an available and missing PSS-
10 (Additional file 1: Table S2). Patients filled in a
Dutch translation which consisted of ten items re-
garding predictability, controllability and life overload
as perceived by the individual during the last month
[21]. Questions are provided in the Additional file 1:
Supplementary Methods and each item of the ques-
tionnaire was rated on a five-point Likert-type scale
(0 = never, 1 = almost never, 2 = sometimes, 3 = fairly
often, 4 = very often) how they felt with a maximum
score of 40. Total scores were calculated after revers-
ing positive items’ scores (questions 4, 5, 7, 8) and
then summing up these scores with the negative
items’ scores [21]. A higher total score indicates a
greater perceived stress response. As there is no pre-
determined cut-off of high psychological stress, results
on this questionnaire were not dichotomized. As ref-
erence, the mean score of PSS-10 obtained in 2387
respondents in the United States was 12.1 for males
and 13.7 for females [29].
Statistics
We tested dichotomous outcomes of markers of inflam-
mation (CRP positivity, MRI positivity and arthritis on-
set). Associations at baseline were tested with logistic
regression with MHI-5 as dependent variable and with
linear regression with PSS-10 as dependent variable.
Longitudinal data of the MHI-5 were assessed with
logistic regression with a generalized estimating equation
(GEE) model with an unstructured matrix and a logit
link function. Longitudinal data on CRP levels and MRI-
detected inflammation scores were analysed with a GEE
model with an unstructured matrix. In all analyses, (at
baseline and follow-up) we corrected for age and gender.
Further, as sub-analysis, we repeated analyses in CSA
patients that also fulfilled the EULAR definition of arth-
ralgia suspicious for progression to RA. To fulfil the
definition patients should have ≥ 3 of these characteris-
tics: joint symptoms of recent onset (duration < 1 year),
symptoms of MCP joints, morning stiffness ≥60 min,
most severe symptoms in early morning, presence of a
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first-degree relative with RA, difficulty with making a fist
and a positive squeeze test of MCP joints [17]. IBM
SPSS v23 (IBM Corp, Armonk, NY, USA) was used. The
significance level was set at 0.05. To adjust for multiple
testing for the ten different comparisons made at base-
line, we applied Bonferroni correction and then p values
< 0.005 were considered significant.
Results
Patient characteristics
Table 1 presents the baseline characteristics of the 241
CSA patients. The mean age was 44 and the majority
was female. Forty-five patients developed clinical syno-
vitis after a median follow-up of 17 weeks; 65% of these
patients fulfilled the 2010 criteria and 91% started
DMARD therapy.
Stress measured at presentation with CSA
At presentation with CSA, 10% (4/39) of patients with
arthritis during follow-up and 12% (24/197) of the total
group of CSA patients had a high psychological stress
response (‘high stress’) according to the MHI-5 (score <
52). This was not different for patients presenting with
or without an elevated CRP (16 versus 11%, p = 0.36), or
with or without subclinical MRI-detected inflammation
(11 versus 13%, p = 0.56, Fig. 1). Also for the continuous
values of CRP and MRI-detected inflammation scores
with stress we did not find any significant relationships
(p = 0.89 and p = 0.90, respectively). Further, we did not
find associations between stress and age, gender, 68-TJC,
self-reported pain, or HAQ-DI. Significant associations
were observed between stress and self-reported fatigue
(odds ratio [OR] = 1.5, (95% confidence interval (95% CI)
1.1; 1.9); p = 0.003) and wellbeing (OR = 1.6, (95% CI 1.3;
2.1); p < 0.001). This means that patients with a high
stress response had 1.5 times more severe fatigue and
they felt 1.6 times more severely affected in their general
wellbeing compared to patients without ‘high stress’.
When analysing the continuous values of the MHI-5,
instead of dichotomized, this showed similar results. We
found no association for patients presenting with or
without an elevated CRP (p = 0.15), or with or without
subclinical MRI-detected inflammation (p = 0.60) and
also not between stress and age, gender, 68-TJC and self-
reported pain. The association between self-reported
fatigue (β = − 2.5 (95% CI -3.4; − 1.5); p < 0.001) and
wellbeing (β = − 3.4 (95% CI -4.5; − 2.3); p < 0.001) were
also found here and additionally we identified associa-
tions between stress and HAQ-DI (β = − 9.2 (95% CI
−14.6; − 3.8); p = 0.001). The latter means that per point
increase in functional disability patients experienced
more severe stress, reflected by a 9.2 lower MHI-5 score
(on a range 0–100).
When analysing the outcome arthritis-onset during
follow-up, there was no association between the percent-
age of patients with a high stress response at baseline
and the number of patients who did and did not develop
clinical arthritis (10 versus 13%, p = 0.68, Fig. 1). Also for
the continuous MHI-5 score this relationship was non-
significant (p = 0.71).
Stress measured during progression to clinical arthritis
At the time of arthritis-onset, the percentage of patients
with a high psychological stress response increased to
31% (p = 0.025). One year later this had decreased to 8%
(p = 0.020, Fig. 2).
Also, inflammation was measured over time in patients
that progressed to clinical arthritis. The CRP levels were
stable while progressing from CSA to clinical arthritis
(mean 9.8 and 9.1 mg/L respectively, p = 0.83) and de-
creased during the first year of treatment (mean 5.5 mg/L;
p = 0.056). Total MRI-detected joint inflammation -scores
increased between presentation with CSA and arthritis-
onset, though this did not reach statistical significance
(mean score 7.1 and 8.5 respectively, p = 0.066). One year
after presentation with clinical arthritis the scores had de-
creased (mean score 6.3).
Then we investigated whether baseline stress associ-
ated with the MRI-detected total inflammation score or
CRP at arthritis onset and this revealed non-significant
relationships (p = 0.11 and p = 0.92).
Stress measured in patients that did not progress to
clinical arthritis
The percentage of patients with a high psychological stress
response among the CSA patients that did not progress to
clinical arthritis during 2-years of follow-up (n = 196) was
stable and ranged between 7 and 13% (p = 0.42, Fig. 2).
Sub-analyses
To verify the main findings done on psychological stress
present at presentation with CSA, we also analysed
Table 1 Baseline characteristics of all 241 CSA patients studied
and of the 186 patients that also completed the PSS-10
MHI-5
(n = 241)
PSS-10
(n = 186)
Age, mean (SD) 44 (9) 44 (13)
Female, n (%) 187 (78) 147 (79)
68-tender joint count, median (IQR) 6 (3–11) 5 (3–10)
CRP (mg/L), median (IQR) 3 (3–5) 3 (3–5)
RF positive (≥ 3.5 IU/mL), n (%) 51 (21) 37 (20)
ACPA positive (≥ 7 U/mL), n (%) 32 (13) 21 (11)
Symptom duration in weeks, median (IQR) 17 (9–31) 18 (10–31)
ACPA anti-citrullinated peptide antibody, CRP C-reactive protein, IQR interquar-
tile range, RF rheumatoid factor, SD standard deviation
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stress responses measured by the PSS-10. The mean
PSS-10 score in all patients was 13.5 (SD 7.6). Patients
that presented with or without an elevated CRP, with or
without subclinical MRI-detected inflammation or who
did and did not develop arthritis did not have higher
stress levels (p = 0.18, p = 0.83 and p = 0.60 respectively,
Fig. 1). We observed significant positive associations at
baseline between stress and self-reported fatigue (β = 0.
94; p < 0.001), wellbeing (β = 1.20; p < 0.001).
Additionally, analyses were repeated in patients that
were identified as CSA by their rheumatologist and also
fulfilled the EULAR definition for CSA (cut-off ≥ 3 items
present), which was fulfilled by 75% of the CSA patients.
The main findings were similar here too. Measuring the
stress response by MHI-5 revealed that the percentage
of patients with ‘high stress’ was not statistically different
between patients presenting with or without an elevated
CRP (16 versus 12%, p = 0.53), with or without MRI-
detected inflammation (14 versus 12%, p = 0.92) or for
patients who did and did not develop arthritis (13 versus
13%, p = 0.92). Also when measuring stress levels with
the PSS-10 no differences were observed for patients with
elevated versus normal CRP, positive or negative MRI-
detected inflammation and between patients with and
without clinical arthritis during follow-up (p = 0.34, p = 0.
91 and p = 0.61, respectively, Additional file 1: Figure S2).
Also in this subgroup of patients, association between
stress (according to both questionnaires) and wellbeing
was statistically significant (p < 0.001). Repeating the lon-
gitudinal analyses on stress in the subgroup of patients
that fulfilled the EULAR definition revealed similar find-
ings as in the total group; both for the patients that pro-
gressed to clinical arthritis as in those that did not
progress (Additional file 1: Figure S3).
Discussion
This longitudinal study assessed associations and time-
relations between the psychological stress response and
inflammation in an early symptomatic phase of develop-
ment of RA. We found no relationship between stress and
either local or systemic inflammation in patients with clin-
ically suspect arthralgia and also no association between
stress and future clinical arthritis development. However,
levels of psychological stress were increased at the visit
when clinical arthritis was identified and decreased during
the first year of treatment. This is the first study that eval-
uated stress in a symptomatic pre-arthritis phase. Al-
though association studies cannot prove causality, the
present data on the time-relationship suggest that stress
may be more a consequence of symptoms and physical
limitations related to the occurrence of early clinical arth-
ritis, or of concerns related to the diagnosis that has just
been made by a rheumatologist, rather than a cause for
the development of inflammatory arthritis or RA.
At presentation with CSA 10% of the patients with arth-
ritis during follow-up had high stress-levels; this percent-
age is similar to that of the general population [24, 30, 31].
Also, the mean PSS-10 levels that we observed (13.5) were
in line with those previously reported in the USA [21, 29].
Previously, we observed that patients with CSA had in-
creased pain levels and that levels of functional disability
already equalled those at the phase of clinically apparent
arthritis. Hence, even though patients with CSA do ex-
perience significant pain and physical limitations [32],
stress levels were not evidently increased. Thus,
although studies in established RA revealed associations
between pain and stress, in the pre-RA stage of CSA the
symptoms themselves apparently did not result in higher
stress levels.
Our longitudinal analyses revealed that at the time of
presentation with clinical arthritis, which generally is the
time when a diagnosis is established, 31% of the patients
experienced a high stress response. This prevalence is
similar to that observed in studies on (established) RA
[24, 31, 33].
Fig. 1 Percentages of patients with high psychological stress measured
by MHI-5 (a) and obtained mean PSS-10 scores (b) in patients who at
presentation with CSA had elevated versus normal CRP levels, did or did
not have MRI-detected subclinical joint inflammation and patients who
did and did not progress to clinical arthritis over time. In A the percent-
age of patients with high perceived psychological stress by MHI-5
(score < 52) are shown. These were not significantly different between
patients with elevated versus normal CRP (7/43 versus 17/154), with or
without MRI-detected inflammation (11/97 versus 12/92) and between
patients who did and did not progress to clinical arthritis over time
(4/39 versus 20/158)). In B the values of psychological stress by PSS-10
are shown. These results were similar. In A whiskers indicate standard
error and in B whiskers indicate standard deviation
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Multiple studies performed in established RA showed
associations between stress (both short-lived stress in-
duced in an experimental setting and stress experienced
in real life) and inflammation [1, 2, 6, 9–14]. Clear asso-
ciations were observed for different markers of systemic
inflammation (CRP and pro-inflammatory cytokines).
Associations with DAS were also observed; interestingly
these associations were stronger with the subjective pa-
rameters of the DAS, specifically patient’s global assess-
ment, evaluator’s global assessment and TJC, whereas
they found no clear associations with SJC and acute
phase reactants [34]. MRI-detected joint inflammation
has never been studied before in relation to the psycho-
logical stress response, neither in patients with CSA nor
in patients with clinically apparent arthritis or RA. Thus
the current observations on inflammation and stress in
CSA are different from that previously reported in
patients with established RA.
The stress response was assessed using two question-
naires. The main analyses were performed using data
obtained by the MHI-5 and results were verified by the
PSS-10. Both questionnaires are brief and have been
shown to have good concordance with larger
questionnaires [24]. In our study, results were similar for
both questionnaires, which shows validity of the results.
Furthermore, by using both questionnaires we observed
associations between the psychological stress response
and fatigue and general wellbeing. These associations
have previously been observed in patients with RA.
Thus, although the main results of this study were nega-
tive, other known associations were also present in
patients with CSA.
Patients with CSA were identified by their rheumatol-
ogists using their clinical expertise. Recently, a EULAR
definition for arthralgia suspicious for progression to RA
was developed to be used on top of the clinical suspicion
of imminent RA. This serves to reduce heterogeneity in
patient groups, which is highly relevant for the execu-
tion of scientific studies and clinical trials in particu-
lar [17, 35]. In this study, we repeated the analyses in
CSA patients that fulfilled this EULAR definition and
similar results were obtained.
Not only stress, but also inflammation was measured
over time. Joint inflammation was evaluated using MRI.
As expected, the MRI inflammation score increased dur-
ing progression to clinical arthritis and decreased during
Fig. 2 Longitudinal data of percentages of patients with high psychological stress by MHI-5 (a), total MRI inflammation scores (b) and CRP levels
(c), in patients presenting with CSA, and during and after the development of clinical synovitis (a, b, c) and frequency of patients with ‘high stress’
over time in CSA patients that did not progress to clinical synovitis (d). In A the percentages of patients with high stress, with all patients who
progressed to clinical arthritis as reference, at baseline 10% (4/39) had ‘high stress’, at arthritis onset 31% (9/29) and 1 year thereafter 8% (2/25).
In B the MRI-detected inflammation scores increased during progression to clinical arthritis (p = 0.066); the number of MRI scans at the final time
point is limited, hence these data were not incorporated in statistical analyses. In D the percentages of patients with high stress, among all CSA
patients who did not develop clinical arthritis during 2 years of follow-up (n = 196) are shown; this percentage remained rather stable (p = 0.42)
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the first year of treatment. Despite a strong tendency in
the data, statistical significance was not obtained. This is
partly explained by a relatively small number of progres-
sors. In addition, MR imaging was made unilaterally of
hand and foot joints and consequently other joints that
developed clinical arthritis were not imaged. Third, the
serial MRIs were scored without information on time
order; this decreased the sensitivity to detect changes
over time and may have resulted in lower scores com-
pared to chronological reading [36]. Importantly, serial
MRIs were not primary evaluated to determine statistical
significant changes in the course of MRI-detected in-
flammation, but rather to compare the time course of
stress to that of the course of inflammation.
This study had some limitations. As for the presence
of missing data, 82% of patients completed the MHI-5
and patients with missing data did not differ from pa-
tients who completed this questionnaire. Data on the
PSS-10 was missing in the oldest part of the cohort,
hence missingness was completely at random. Second,
the role of acute and chronic stress on inflammation
may be complex [3], here we measured the psychological
stress experienced by patients during the last month.
We did not collect data on other psychological factors
(e.g. coping mechanisms, social support, psychiatric co-
morbidities) or life events to account for in measure-
ments that could have played a role in arthritis
commencement. Also the occurrence of major life
events in childhood or more recently in adulthood was
not specifically investigated and effects of such major
stressors were not evaluated in this study. In addition,
regarding systemic inflammation, we only determined
CRP levels and did not evaluate other markers, like cyto-
kines. In addition, cortisol or other hormones were not
assessed. Further, an important remark could be that
CRP values can be increased by diseases not related to
the joints. Only 27 of 241 patients had CRP values > 10;
one of these patients had a comorbidity that may have
influenced the CRP level (benign prostate hypertrophy
with chronic inflammation). Exclusion of this patient did
not change the results (data not shown). Finally, early
identification of CSA is difficult, and therefore the size
of the current study (241 CSA patients with longitudinal
follow-up) is considerable. However, power to detect as-
sociations with stress with very small effect sizes may
have been insufficient. The previously observed associ-
ation between life events and risk for RA reported an
OR of 1.1 and effects of this size will remain undetected
in the present data.
Conclusions
In conclusion, this study is the first that evaluated the
stress response in a symptomatic pre-arthritis phase and
also contained longitudinal data. In the phase of
arthralgia, high stress levels were infrequent. The pro-
portion of patients with a high stress response increased
at the time of clinical arthritis development and diagno-
sis. Hence, the course of stress levels paralleled or
followed, but not preceded, the course of inflammation
in this study. This temporal relationship as well as the
lack of an association of stress with local or systemic in-
flammation in the phase of arthralgia may suggest that
in this very early disease phase when disease chronicity
has not yet been established, stress may have little influ-
ence on the inflammatory response, and therefore this
implies that it does not mediate the progression from
arthralgia to clinical arthritis. Although further studies
on the association of stress and inflammation in pre-RA
are required, the vicious circle of stress and inflamma-
tion as observed in patients with established RA was not
yet observed in the phase of CSA.
Additional file
Additional file 1: Supplementary material. (DOCX 195 kb)
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